Literature DB >> 20843079

Acid-induced aggregation of human monoclonal IgG1 and IgG2: molecular mechanism and the effect of solution composition.

Sanjay B Hari1, Hollis Lau, Vladimir I Razinkov, Shuang Chen, Ramil F Latypov.   

Abstract

The prevention of aggregation in therapeutic antibodies is of great importance to the biopharmaceutical industry. In our investigation, acid-induced aggregation of monoclonal IgG1 and IgG2 antibodies was studied at pH 3.5 as a function of salt concentration and buffer type. The extent of aggregation was estimated using a native cation-exchange chromatography (CEX) method based on the loss of soluble monomer. This approach allowed quantitative analysis of antibody aggregation kinetics for individual and mixed protein solutions. Information regarding the aggregation mechanism was gained by assessing stabilities of intact antibodies relative to their Fc and Fab fragments. The role of protein thermodynamic stability in aggregation was deduced from differential scanning calorimetry (DSC). The rate of aggregation under conditions mimicking the viral inactivation step during monoclonal antibody (mAb) processing was found to be strongly dependent on the antibody subclass (IgG1 vs IgG2). At 25 °C, IgG1s were resistant to low pH aggregation, but IgG2s aggregated readily in the presence of salt. The observed distinction between IgG1 and IgG2 aggregation resulted from differential stability of the corresponding C(H)2 domains. This was further confirmed by experimenting with an IgG1 molecule containing an aglycosylated C(H)2 domain. Interestingly, comparative analysis of two buffer systems (based on acetic acid vs citric acid) revealed differences in mAb aggregation under identical pH conditions. Evidence is provided for the importance of the total acid concentration for antibody aggregation at low pH. The effects of C(H)2 instability and solution composition on aggregation are significant and deserve careful consideration during the development of mAb- or Fc-based therapeutics.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20843079     DOI: 10.1021/bi100841u

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  40 in total

1.  Elucidation of acid-induced unfolding and aggregation of human immunoglobulin IgG1 and IgG2 Fc.

Authors:  Ramil F Latypov; Sabine Hogan; Hollis Lau; Himanshu Gadgil; Dingjiang Liu
Journal:  J Biol Chem       Date:  2011-11-14       Impact factor: 5.157

2.  Structure and function of purified monoclonal antibody dimers induced by different stress conditions.

Authors:  Rajsekhar Paul; Alexandra Graff-Meyer; Henning Stahlberg; Matthias E Lauer; Arne C Rufer; Hermann Beck; Alexandre Briguet; Volker Schnaible; Thomas Buckel; Sabine Boeckle
Journal:  Pharm Res       Date:  2012-04-05       Impact factor: 4.200

3.  Generation and comparative characterization of glycosylated and aglycosylated human IgG1 antibodies.

Authors:  Dmitrij Hristodorov; Rainer Fischer; Hannah Joerissen; Beate Müller-Tiemann; Heiner Apeler; Lars Linden
Journal:  Mol Biotechnol       Date:  2013-03       Impact factor: 2.695

4.  Rational design of therapeutic mAbs against aggregation through protein engineering and incorporation of glycosylation motifs applied to bevacizumab.

Authors:  Fabienne Courtois; Neeraj J Agrawal; Timothy M Lauer; Bernhardt L Trout
Journal:  MAbs       Date:  2016       Impact factor: 5.857

5.  Engineering an improved IgG4 molecule with reduced disulfide bond heterogeneity and increased Fab domain thermal stability.

Authors:  Shirley J Peters; C Mark Smales; Alistair J Henry; Paul E Stephens; Shauna West; David P Humphreys
Journal:  J Biol Chem       Date:  2012-05-18       Impact factor: 5.157

6.  Computational design of a pH-sensitive IgG binding protein.

Authors:  Eva-Maria Strauch; Sarel J Fleishman; David Baker
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-31       Impact factor: 11.205

7.  Effects of subclass change on the structural stability of chimeric, humanized, and human antibodies under thermal stress.

Authors:  Takahiko Ito; Kouhei Tsumoto
Journal:  Protein Sci       Date:  2013-09-30       Impact factor: 6.725

8.  Classification and characterization of therapeutic antibody aggregates.

Authors:  Marisa K Joubert; Quanzhou Luo; Yasser Nashed-Samuel; Jette Wypych; Linda O Narhi
Journal:  J Biol Chem       Date:  2011-03-25       Impact factor: 5.157

9.  Engineering an IgG Scaffold Lacking Effector Function with Optimized Developability.

Authors:  Frederick W Jacobsen; Riki Stevenson; Cynthia Li; Hossein Salimi-Moosavi; Ling Liu; Jie Wen; Quanzhou Luo; Kristine Daris; Lynette Buck; Sterling Miller; Shu-Yin Ho; Wei Wang; Qing Chen; Kenneth Walker; Jette Wypych; Linda Narhi; Kannan Gunasekaran
Journal:  J Biol Chem       Date:  2016-12-19       Impact factor: 5.157

Review 10.  With or without sugar? (A)glycosylation of therapeutic antibodies.

Authors:  Dmitrij Hristodorov; Rainer Fischer; Lars Linden
Journal:  Mol Biotechnol       Date:  2013-07       Impact factor: 2.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.